- Home
- IPSC vs INMB Comparison
IPSC vs INMB Comparison
Compare IPSC & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- INMB
- Stock Information
- Founded
- IPSC 2019
- INMB 2015
- Country
- IPSC United States
- INMB United States
- Employees
- IPSC N/A
- INMB N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- IPSC Health Care
- INMB Health Care
- Exchange
- IPSC Nasdaq
- INMB Nasdaq
- Market Cap
- IPSC 45.4M
- INMB 49.2M
- IPO Year
- IPSC 2021
- INMB 2019
- Fundamental
- Price
- IPSC $0.55
- INMB $1.71
- Analyst Decision
- IPSC Strong Buy
- INMB Hold
- Analyst Count
- IPSC 6
- INMB 3
- Target Price
- IPSC $3.00
- INMB $4.30
- AVG Volume (30 Days)
- IPSC 1.5M
- INMB 382.6K
- Earning Date
- IPSC 11-13-2025
- INMB 10-30-2025
- Dividend Yield
- IPSC N/A
- INMB N/A
- EPS Growth
- IPSC N/A
- INMB N/A
- EPS
- IPSC N/A
- INMB N/A
- Revenue
- IPSC $113,337,000.00
- INMB $50,000.00
- Revenue This Year
- IPSC $1,589.94
- INMB $191.43
- Revenue Next Year
- IPSC N/A
- INMB $12,299.51
- P/E Ratio
- IPSC N/A
- INMB N/A
- Revenue Growth
- IPSC 4122.69
- INMB 19.05
- 52 Week Low
- IPSC $0.34
- INMB $1.38
- 52 Week High
- IPSC $1.83
- INMB $11.64
- Technical
- Relative Strength Index (RSI)
- IPSC 52.98
- INMB 55.44
- Support Level
- IPSC $0.46
- INMB $1.46
- Resistance Level
- IPSC $0.56
- INMB $1.62
- Average True Range (ATR)
- IPSC 0.04
- INMB 0.10
- MACD
- IPSC 0.00
- INMB 0.03
- Stochastic Oscillator
- IPSC 76.21
- INMB 97.14
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.